

RESTASIS[®] is the #1-prescribed branded eye drop^{1,*}

For patients with decreased tear production presumed to be due to ocular inflammation associated with Chronic Dry Eye

RESTASIS® helps patients

make more of their own real tears²

RESTASIS® has been on the market for nearly 2 decades, prescribed for an estimated **9.28 million patients** since launch in 2003^{3,†}



*Rolling data from January 2020 to February 2021. †Rolling data from 2003 to 2020.

Indications and Usage

RESTASIS® and *RESTASIS MultiDose*® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information Contraindications

RESTASIS® and *RESTASIS MultiDose*® are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Please see additional Important Safety Information on reverse side.



RESTASIS® has broad access and is covered for the majority of commercial and Medicare Part D patients^{4,*}

Most eligible commercially-insured patients may pay as little as \$0[†] for a 90-day supply


CoverMyMeds and PARx are also available for prior authorization support for you and your offices.

*Data includes RESTASIS® only and does not include RESTASIS MultiDose®. Data as of September 2021 and are not a guarantee of coverage. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with the applicable insurer. Allergan, an AbbVie company, does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

[†]Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for RESTASIS **or RESTASIS** MultiDose**. Offer not valid for patients enrolled in Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. **See My Tears, My Rewards** Program Terms, Conditions, and Eligibility Criteria at https://www.restasis.com/termsofuse/termsandconditions5.**

Help your new and existing patients receive RESTASIS® at the pharmacy

- You have the option to write "Dispense as Written," or other state-specific verbiage required to help your patients receive a branded product, on prescriptions
- Check that the pharmacy runs the patient's insurance for the prescribed medication so that the patient is fully informed on potential out-of-pocket costs



Important Safety Information (continued) Warnings and Precautions

Potential for Eye Injury and Contamination: Be careful not to touch container tip to your eye or other surfaces to avoid potential for eye injury and contamination.

Use With Contact Lenses: RESTASIS® and *RESTASIS MultiDose*® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® and *RESTASIS MultiDose*® ophthalmic emulsion.

Adverse Reactions

In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/restasis_pi.pdf

References: 1. IQVIA, Rolling 12 months ending 2-21. Pulled from AIMM+. **2.** RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% [prescribing information]. Irvine, CA: Allergan, Inc.; 2017. **3.** Data on file. Allergan, Inc., 2021; Non-IP (Commercial) Document. **4.** Managed Markets Insight & Technology, LLC™, a trademark of MMIT Database, as of September 2021.

